Zimbabwe has rejected a substantial US health deal worth $367m (£272m) over five years over Washington's demand for sensitive information.
The decision was revealed following a government memo from December was leaked, which showed President Emmerson Mnangagwa deemed the deal was "skewed".
An official representative has since clarified that the US was requesting biological samples for research and profit while was unwilling to guarantee the benefits from future vaccines.
"We are forced to start the challenging and unfortunate task of ending our health assistance in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the US had donated over $1.9bn for health programmes to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has urged further negotiations to secure a deal acceptable to all parties so the country's vital HIV programme can continue.
Broader Context
This rejection follows a comparable case in neighbouring Kenya, where a court blocked a related health funding agreement after legal challenges were raised about the safety of citizens' medical information.
Since returning to office recently, US President Donald Trump has reduced foreign aid and shut down the key foreign aid agency.
USAID had administered assistance for the American government, but Trump stated its spending was "inefficient" and his administration was pursuing government-to-government deals to boost openness and responsibility.
As per reports, 16 nations in Africa have so far agreed to similar agreements, representing over $18.3bn of fresh investment.
Details of the Declined Deal
The money for Zimbabwe was intended to supported "tackling HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this collaboration could have provided immense benefits for Zimbabwean communities, particularly the 1.2 million presently on HIV treatment via American-funded programmes," the Ambassador said.
However, official spokesman Nick Mangwana said the arrangement was "unfair".
"Our nation was requested to provide its genetic material and health information for a long time, without any equivalent promise of benefiting from any scientific breakthroughs – like new medicines or tests – that might be developed from that shared data," Mangwana explained.
"Effectively, our nation would supply the raw materials for medical research without any certainty that the final treatments would be accessible to our people if a new pandemic arise."
National Interest and International Frameworks
He also pointed out that the American exit from the global health body and its pursuit of bilateral deals were disrupting frameworks already established via the international organization.
Mangwana gave as an example its Pathogen Access and Benefit Sharing framework created to manage future global health emergencies.
"This framework is intended to ensure that when a country provides its information, the resulting advantages – including vaccines and treatments – are shared equitably, not commercialised exclusively by those with the resources to create them."
The government's concerns regarding the US deal "are not meant as opposition to America," Mangwana stressed.
"We encourage further dialogue with our American counterparts on how future collaboration might be structured in a manner that honours the independence and dignity of both nations."
Health Experts Response
The Zimbabwe College of Public Health Physicians (ZCPHP) said it recognised the government's concerns, but suggested that talks should continue given that much of the nation's Aids initiatives depended on external financing.
"Where technical issues exist, including those involving data governance or agreement terms, these can frequently be resolved via technical clarification and mutually agreed protections," it said.
This impasse emphasises the continuing tensions between receiving vital international aid and protecting a country's data in an ever more data-driven world.